期刊
ATHEROSCLEROSIS
卷 219, 期 2, 页码 734-736出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2011.09.015
关键词
Rheumatoid arthritis; Endothelial function; Arterial stiffness; Pulse wave velocity; Flow-mediated dilatation; Tocilizumab; Interleukin-6
Interleukin (IL)-6 is a pleiotropic proinflammatory cytokine involved in the pathogenesis of both atherosclerosis and rheumatoid arthritis. The role of the IL-6/IL-6 receptor pathway in the documented acceleration of atherosclerosis in rheumatoid arthritis has not been examined. In a non-randomized prospective pilot study we asked whether endothelial dysfunction, defined as impaired flow mediated dilatation (FMD), and aortic stiffness, assessed by pulse wave velocity (PWV) improve after 3 and 6 monthly therapeutic infusions of the anti-IL-6 receptor antibody tocilizumab for active rheumatoid arthritis. We found that FMD increased from 3.3 +/- 0.8 to 4.4 +/- 1.2 to 5.2 +/- 1.9% (p = 0.003), whereas PWV decreased from 8.2 +/- 1.2 to 7.7 +/- 1.3 to 7.0 +/- 1.0 m/s (p < 0.001). Whether these beneficial arterial changes are direct effects of the IL-6/IL-6 receptor pathway inhibition, maintained over time and translate into better clinical outcome warrants further studies. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据